East Lancashire Prostate Cancer Support Group Newsletter





Volume3

Issue8

Date August 2014

£1million boost for cancer care in East Lancashire

http://www.lancashiretelegraph.co.uk http://www.lancashiretelegraph.co.uk/trade_directory/

What's Inside

£1 Million Boost P1

B*** to PCa!** P3

Service User Focus Group Seminar

P2 P4 P5 P6 P7

Abiraterone

ne P8

Fiasco!

10:54am Wednesday 20th August 2014

By Lawrence Dunhill

CHARITY bosses have announced a new £1 million fund to boost cancer care in East Lancashire, in a bid to tackle some of the worst 'death rates' for the condition in England.

The Macmillan charity has teamed up with the NHS to launch a three-year improvement programme, which promises to involve all 90 doctors' surgeries in the area.

It comes after new figures revealed the number of premature cancer deaths in Burnley and Hyndburn were well above the national average between 2010 and 2012.

The under-75s cancer mortality rate for

Burnley was the second highest in the North West, at 205 per 100,000. Hyndburn's rate was 174 per 100,000, compared to the national average of 146 per 100,000.

The 'Cancer Service Redesign' for East Lancashire is among of the first of its kind, as only a handful of other 'hotspot' boroughs have so far received funding from the charity.

The cash will be spent on increasing cancer awareness and diagnosis among GPs, to ensure the disease is caught at an earlier stage in more cases.

It will also be focused on boosting screening rates and offering extra support to patients once their treatment has finished.

Jeremy Such, Macmil-

lan's development manager for Lancashire, said: "I'm very excited about this partnership and the project we're undertaking to transform cancer care in East

Lancashire and Blackburn with Darwen.

"The project will provide better care and support for people affected by cancer at every stage, from the moment of diagnosis, through treatment and beyond.

"We want to improve outcomes for patients and deliver a better patient experience so that no one faces cancer alone."

 If you are affected by cancer and need information or support, call 0808 808 00 00 or visit

www.macmillan.org.

Macmillan Pennine Lancashire Cancer Improvement Partnership

This article follows on from the article on the front page.

The Introduction of associated support groups to the Blackburn with Darwen Council's Service User Focus Group was attended by representative members of our support group, (Dave Riley, Stuart Marshall, John Goulding, & Leon D Wright. Other Support groups were also in attendance providing a very good networking opportunity



The meeting was held at the Mercure Blackburn Dunkenhalgh Hotel & Spa, Blackburn Road, Clayton-le Moors. The meeting was very informative, covering the issues of social and community care to improve the patient experience in the treatment of their cancer

Macmillan Pennine Lancashire Cancer Improvement Partnership (MCIP)

The Vision of the MCIP is to provide a comprehensive service redesign that enhances seamless and coordinated care pathways, embeds best practice within aspects of cancer care across Social, Primary, and Acute Care, and delivers better outcomes and a better experience for people affected by cancer in Pennine Lancashire

- Provision information & training of staff
- Access to physical activity
- Support primary care
- Holistic Needs Assessment
- Risk Stratification of patients.
- Care Planning.
- Use of Treatment Summary

Pages 5—8 Cover the Seminar Presentation on Wednesday 13th August 2014 it is a PowerPoint presentation which will be available to view on the www.elpcsg.com on the Service User Focus Group page.

Volume 3 Issue 8 Page 3



Contact Information

Tel: 07548 033930 E Mail leondwright4@gmail.com

From Left to Right Hazel Goulding (Treasurer) Leon D Wright (IT Admin) Stuart Marshall (Secretary) Steve Laird (Vice Chairman) Dave Riley (Chairman)

We are a group of local people who know about prostate cancer. We are a friendly organisation dedicated to offering support to men who have had or who are experiencing the effects of this potentially life threatening disease.

The East Lanc's Prostate Cancer Support Group offers a place for free exchange of information and help for local men and their supporters (family and friends) who may be affected by this increasingly common form of male cancer.

At each meeting we strive to be a happy, supportive and upbeat group of people; encouraging open discussion on what can be a very difficult and perhaps for some an embarrassing subject. We have lively, informative, interactive, sharing and above all

B***** to PCa

We've had to learn a whole new lexicon New words and medical babble With such increased vocabulary We should be bloody great at Scrabble!

A new website for our ailments To help that constant toilet dash It's called bladder trouble dot co UK Forward slash, slash, slash, sla!

The Prostatectomy boys amongst us Still cross our legs and flinch
The surgeon cuts away our prostate
...And we lose that vital inch!

And the ladies all remember Those spontaneous, frantic humps Now it needs to be pre-ordered Using injections, pills and pumps!

But it has its compensations And it is why we're still a catch After taking you to heaven There's the bliss of no wet patch!

And the side effects of hormones Can play havoc with our bits Girl's you're not the only ones Who will hear those words, 'nice tits!"

We still keep hedonistic lifestyles But our demands have changed in tone It's no longer, 'pass the e tabs' It's, 'pass the abiraterone'!

Now ladies we salute you You stand by us every knock Your love is so unswerving You really are our rock!

But let's just restore some balance Keep our male egos all alive Why is it as a gender, You lot still can't bloody drive?!

Now no one chose to join this club It's just how our lives unfurled But, to steal the words of Carlsberg "Probably the best club in the world!"

So let's continue with our battle Fight this bastard all the way The tide it is a turning And we will win through one day!

So b****** then to PCa Laugh at your Gleason score And pledge that everyone of us Will be back next year for more!

















Macmillan Pennine Lancashire Cancer Improvement Partnership

Service User Focus Group 13th August 2014



Helen Hyndman Macmillan Pennine Lancashire Cancer Improvement Partnership Project Facilitator



Vision

- > A comprehensive service redesign that:
 - o Embeds seamless and coordinated care pathways.
 - Embeds best practice within aspects of cancer care across Social, Primary and Acute Care.
 - o Delivers better outcomes.
 - o Delivers a better patient experience.
 - o Is underpinned by service user involvement.





Social/Community Care Work stream

- Provision of information for patients, carers and families in a range of community and primary care settings across Pennine Lancashire.
- > Training for key primary and community staff to provide information.
- Provision of increased access to physical activity options and programmes INFOPOINT
- Operation of Macmillan Solutions.

Project Aims

care at all stages of a patient

ordinated care pathways

aspects of cancer care

 Deliver better outcomes · Deliver better patient

journey, which will:

experience

Project Elements

· Primary Care Acute Care **Underpinning Ethos:**

Dedicated workstreams:

· Social / Community Care

· Service User Involvement



Primary Care Work stream

- Primary Care Change Management Programme including:
 - o Practice "Cancer Care Team".
 - o Cancer prevention and awareness.
 - o Increased uptake of bowel screening.
 - Significant Event Analysis on emergency cancer presentations.
 - o Implementation of a standardised, quality 2 week wait referral system.
 - o Practice Nurse Training CCR, IP's.

Acute Work stream

- The implementation of key tools and best practice, as detailed in the Recovery Package, across identified tumour sites:
 - o HNA, Care Planning, IP's
 - Risk Stratification
 - Use of Treatment Summaries
 - Changes to support and FU
 - o Development of a rapid re-access service

Service User Involvement



- Consultation with service users to influence content of project.
- Engagement with ethnic minority and other less heard groups.
- Enabling people from PL to have an active voice in development of cancer services.
- Collaborative working between health professionals and patients to develop patient led cancer services.
- National policies implemented with input from people affected by cancer.

Blackburn with Darwen Clinical Commissioning Group





East Lancashire
Clinical Commissioning Group

What do you see as your role?





A charity says a decision by the NHS in England to reject a drug for men with prostate cancer is a "fiasco". (BBC News Health Nick Triggle)

Abiraterone is already given to patients at the end-of-life after chemotherapy as it gives patients an extra few months.

But the National Institute for Health and Care Excellence said it was not cost-effective to offer it earlier.

It said while the drug improved quality of life, it was unclear whether it had the same impact on life expectancy.

This was due to problems with the research data, NICE said, claiming the trial was finished early - something disputed by the drug's makers Janssen.

'Vital opportunity'

Instead, patients will have to rely on their doctors applying to the Cancer Drugs Fund, a special pot set aside for cancer drugs not routinely available on the NHS.

Some 3,000 patients have done this in the last year, but that fund is due to end in 2016.

Owen Sharp, chief executive of Prostate Cancer UK, the largest men's health charity, said the whole process was "a fiasco".

He criticised NICE's inflexibility and the drug company's results-gathering process, saying: "This decision is a kick in the teeth for men with advanced prostate cancer.

"For many this presented a vital opportunity for extra time with loved ones and a chance to delay chemotherapy and the debilitating side-effects which come with it."

The decision comes just a week after <u>NICE rejected a breast cancer drug called Kadcyla</u> - again leaving the Cancer Drugs Fund as the only option for patients.

The drug normally costs £3,000 a month, but is given to the NHS for a discounted price after negotiations two years ago when the ruling on its use after chemotherapy was reached.

'Very disappointed'

At the time it was hailed as a real breakthrough for patients with aggressive prostate cancer.

NICE chief executive Sir Andrew Dillon said he was disappointed not to be able to recommend abiraterone for use before chemotherapy.

He told BBC Radio 4's Today programme that pharmaceutical firms had to "balance their desire to make a profit" with the reality that the NHS had to meet all its needs.

"If we don't put in place arrangements to require drug companies... to look critically at what they are asking the NHS to pay, it will simply be a question of offering the keys to the safe and we can't do that," Sir Andrew said.

As well as the dispute about the way the research was conducted, this ruling has caused controversy because of the way NICE carried out the assessment.

When it assessed the drug for use after chemotherapy in 2012, NICE adopted its end-of-life criteria, which means it is willing to pay more.

For the latest assessment, it was judged to be a standard treatment.

The final guidance is expected later in the year, but major changes at this stage are considered unlikely.

While it will apply to England, the other UK nations also consider NICE's findings.

Janssen medical director Dr Peter Barnes said the firm was "very disappointed" and would appeal against the decision.

15/08/2014